Delivery Order SPE2DR25D3008-SPE2DR26F3N8A
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,559.84 on December 23, 2025, for the supply of Ibrance 100 mg tablets (7-count packaging). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of January 15, 2026. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 28, 2025, for the supply of Ibrance 100 mg tablets in a seven-count configuration, with a ceiling value of $8,559.84 and firm fixed pricing. This is a non-set-aside competitive award with an ultimate completion date of December 19, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,122.48 on August 12, 2025, for the supply of Ibrance 100 mg tablets (7-unit package). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $8,555.21 to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Ibrance 125 mg tablets (7-count packages). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The contract is scheduled for completion by December 31, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $16,244.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (7-count packaging) on September 9, 2025, with a completion date of September 30, 2025. This firm fixed-price delivery order represents a non-competitive set-aside arrangement and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- The Defense Logistics Agency awarded a $8,123.96 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ibrance 75 mg tablets (quantity 7 units). This competitive, non-set-aside contract carries a firm fixed price and is scheduled for completion by September 5, 2025. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count package) on August 1, 2025, with an ultimate completion date of August 22, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this...
- The Defense Logistics Agency awarded a $8,559.84 delivery order to AmerisourceBergen Drug Corp on December 16, 2025, for the supply of Ibrance 100 mg capsules (21-count). This competitive, non-set-aside contract represents a firm fixed price delivery order with an ultimate completion date of January 8, 2026, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is a child contract issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $8,122.48 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (quantity 7s) on August 26, 2025, with an ultimate completion date of September 17, 2025. This is a firm fixed price delivery order with no set-aside designation, issued competitively to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count package) on September 5, 2025, with an ultimate completion date of September 26, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 vehicle running through...
- SPE2DR25D3008Indefinite Delivery Contract
- SPE2DR25D3008-SPE2DR26F3N8ADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,559.84 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (7-count units) on December 8, 2025, with a completion date of December 30, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitively awarded delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order falls within AmerisourceBergen's role as a critical pharmaceutical distributor supporting the Defense Health Agency and other federal healthcare systems. The company's DLA prime contract serves as a comprehensive global pharmaceutical support vehicle enabling supply of brand-name medications, generic drugs, vaccines, and specialized medical commodities across multiple therapeutic domains to military healthcare programs worldwide. Ibrance (palbociclib) is a targeted cancer therapy used primarily in the treatment of breast cancer, reflecting the breadth of oncology medications supplied through this DLA medical supply chain contract.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.6k | 12/7/25 |